Why the study?
Does amlodipine/benazepril improve blood pressure control and reduce costs compared to amlodipine, felodipine, or nifedipine in patients with moderate to severe hypertension failing initial therapy?
Does amlodipine/benazepril improve blood pressure control and reduce costs compared to amlodipine, felodipine, or nifedipine in patients with moderate to severe hypertension failing initial therapy?
Answers are grounded in this paper and cite their sources.
In a decision analysis model, amlodipine/benazepril combination therapy was more effective and less costly than high-dose monotherapies for patients with moderate to severe hypertension failing initial treatment.
The purpose of the study was to compare the costs and outcomes of antihypertensive therapeutic treatments (amlodipine besylate 10mg, felodipine 10mg, nifedipine 60mg, amlodipine/benazepril 2.5mg/10mg) for managed care patients with moderate to severe hypertension who had previously failed initial drug therapy (beta blockers or diuretics per JNC-VI). A decision analysis model was developed to simulate hypertension management for a hypothetical cohort of patients with moderate to severe hypertension in a Managed Care Organization (n=200,000). Patients were distributed evenly between the four therapies (n=50,000). The model follows patients over the course of one year during which time patients may experience adverse drug reactions and success or failure of blood pressure control. Efficacy and tolerability estimates were obtained from a published meta-analysis and literature. Medical management was based on results from a physician survey. Costs included in the model were drug acquisition, routine follow-up, management of blood pressure control failure and adverse events. Model parameters were varied to test the stability of the conclusions (e.g., efficacy and tolerability were varied above and below the baseline). Approximately 93% of patients responded to second-line therapy with amlodipine/benazepril at the end of one year, compared with 92% in the felodipine arm, 91% in the amlodipine besylate arm and 88% in the nifedipine arm. The percentage of patients who remained on initial therapy and did not require treatment modification (e.g., increase in dose, addition of a concomitant medication or a medication switch) due to drug intolerability or lack of blood pressure control was higher in the amlodipine/benazepril arm. The cost of amlodipine/benazepril was lower than the total cost of care of the other treatments: $51,700,000 for amlodipine/benazepril versus $60,900,000, $58,100,000 and $60,950,000 for nifedipine, felodipine and amlodipine besylate, respectively. Increasing efficacy by one standard deviation resulted in a greater percentage of patients achieving BP control at a lower cost of treatment for all regimens. Amlodipine/benazepril remained the most effective at a lower cost because patients required fewer treatment modifications. Decreasing the efficacy estimate resulted in a slightly greater percentage of amlodipine besylate patients achieving goal compared with amlodipine/benazepril patients, but at a higher cost. Amlodipine/benazepril therapy resulted in the greatest number of patients achieving BP control and maintaining their initial therapy at a lower treatment cost.
No takes yet. Share an insight, caveat, or question.
Simon Lyck Bjært Sørensen (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: